Table 2.
Demographic and clinical characteristic of IA and non-IA patients.
| aspBIOmics consortium + UHS-GHV-PCR-AGA-UCSC-MORE populations | ||||
|---|---|---|---|---|
| Overall (n = 834) | IA patients (n = 157) | Non-IA patients (n = 677) | P-value | |
| DEMOGRAPHIC VARIABLES | ||||
| Age | 52.89 ± 15.95 | 53.78 ± 15.37 | 52.69 ± 16.07 | NS |
| Sex ratio (male/female) | 1.28 (466/362) | 1.86 (99/53) | 1.18 (367/309) | 0.015 |
| HEMATOLOGICAL DISEASE | ||||
| AML | 571 (68.62) | 112 (71.33) | 459 (68.00) | NS |
| ALL | 77 (09.25) | 18 (11.46) | 59 (08.74) | NS |
| Other | 184 (22.11) | 27 (17.19) | 157 (23.25) | NS |
| HSCT | 380 (45.56) | 72 (45.85) | 308 (45.49) | NS |
| PROPHYLAXIS* | ||||
| Ever use of prophylaxis | 386 (46.28) | 56 (35.67) | 330 (48.74) | 0.006 |
| Never use of prophylaxis | 232 (27.81) | 54 (34.39) | 178 (26.29) | 0.006 |
HSCT, Hematopoietic stem cell transplantationl; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; UHS, University hospital of Salamanca (Spain); GHV, General hospital of Valencia (Spain); PCRAGA clinical trial (EU clinical trial number: 2010-019406-17); UCSC, Università Cattolica del S. Cuore, Rome; MORE, University of Modena and Reggio Emilia, AOU Policlinico, Modena (Italy). P values ≤ 0.05 were considered significant and are highlighted in bold.
*
Some patients had several prophylactic drugs.
Data on underlying disease and sex was not available for 2 and 6 patients, respectively.
Prophylaxis status was unknown for 216 patients.